Large investor Jorey Chernett reports 9.45% OKYO Pharma (OKYO) stake

Rhea-AI Filing Summary

OKYO Pharma Ltd disclosed that investor Jorey Chernett has filed Amendment No. 2 to a Schedule 13G reporting a significant stake in the company’s common shares. Chernett beneficially owns 3,802,194 shares, representing 9.45% of the outstanding common stock as of the event date.

The filing states that Chernett has sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive authority. It also certifies that the securities were not acquired to change or influence control of OKYO Pharma Ltd, but rather as a passive investment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

OKYO Pharma Ltd

(Name of Issuer)

Common

(Title of Class of Securities)

G6724L116

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G6724L116

1

Names of Reporting Persons

Chernett Jorey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,802,194.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,802,194.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,802,194.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: OKYO Pharma Ltd
(b)	Address of issuer's principal executive offices: Floor 4, 14/15 Conduit St, LONDON, UNITED KINGDOM, W1S 2XJ.
Item 2.
(a)	Name of person filing: Jorey Chernett
(b)	Address or principal business office or, if none, residence: 6222 Indianwood Trail, Bloomfield Hills, MI 48301
(c)	Citizenship: US
(d)	Title of class of securities: Common
(e)	CUSIP No.: G6724L116
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,802,194
(b)	Percent of class: 9.45%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,802,194
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,802,194
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Chernett Jorey

Signature:	/s/Jorey Chernett
Name/Title:	Individual
Date:	02/13/2026

FAQ

What does the Schedule 13G/A filing reveal about OKYO (OKYO) ownership?

The filing shows that Jorey Chernett beneficially owns 3,802,194 OKYO Pharma common shares, equal to 9.45% of the class. This indicates a large passive shareholder with significant influence through voting and dispositive power over these shares.

Who is the reporting person in the OKYO (OKYO) Schedule 13G/A Amendment No. 2?

The reporting person is Jorey Chernett, a United States citizen. The filing lists his address as 6222 Indianwood Trail, Bloomfield Hills, MI 48301 and classifies him as an individual investor rather than a broker, bank, or institutional entity.

How many OKYO (OKYO) shares does Jorey Chernett control and what percentage is this?

Jorey Chernett beneficially owns 3,802,194 OKYO Pharma common shares, representing 9.45% of the outstanding class. He has sole power to vote and dispose of all these shares, with no shared authority reported in the filing.

Is Jorey Chernett’s stake in OKYO (OKYO) intended to influence control of the company?

According to the certification, the securities were not acquired and are not held for the purpose of changing or influencing control of OKYO Pharma. The position is reported as a passive investment under Schedule 13G rules, not an activist or control-seeking stake.

What is the relevant event date for the OKYO (OKYO) Schedule 13G/A ownership information?

The event date that triggered this Schedule 13G/A Amendment No. 2 is December 31, 2025. The reported ownership of 3,802,194 common shares and 9.45% of the class reflects Chernett’s position as of that date.

Does the OKYO (OKYO) Schedule 13G/A indicate any group or subsidiary involvement?

No. The filing states that Items 6, 7, 8, and 9, which address ownership on behalf of others, subsidiaries, groups, or group dissolution, are Not Applicable. The reported OKYO Pharma stake is attributed solely to individual investor Jorey Chernett.